Store
IVD Trends and Market Update, March 2022
Publication Date: March 23, 2022
Tags: Coagulation, COVID-19, Genetic Diseases, Hematology, Histology and Cytology, Immunoassay, In Vitro Diagnostics (IVD), Infectious Diseases, Molecular Diagnostics, Oncology and Cancer, Patient Monitoring and Telehealth, Point-of-Care (POC) Testing
Pages: 50
SKU: 22-028
Stay informed with the latest trends and developments in the IVD market with IVD Trends and Market Update, March 2022 from Kalorama Information. The report reflects the latest industry insights as of Q1 2022. This comprehensive report examines the critical factors driving growth, major trends, and the ongoing impact of COVID-19 on the IVD industry.
Report Highlights:
- Market Drivers in 2022:
- Analysis of key factors influencing market growth throughout the year.
- Detailed exploration of how COVID-19 continues to impact the IVD market.
- Major Trends in 2022:
- Identification of significant trends shaping the market, including product innovations and new developments.
- Product Trends and New Developments:
- Insight into emerging technologies such as next-generation sequencing (NGS), personalized medicine, and mass spectrometry.
- Focus on core market interests including immunochemistry, point-of-care (POC) testing, and molecular diagnostics.
Market Dynamics:
- Innovation and Development: The IVD market is constantly evolving with new products, changes in global health spending, regulatory shifts, and emerging disease trends.
- Demand and Technology Movement: Comprehensive coverage of how the demand for testing and advancements in technology are driving gains across most areas of the IVD market.
Expert Insights:
- Kalorama Information provides a thorough overview of the IVD market, leveraging the extensive experience of its authors and a commitment to delivering the most accurate data available.
- This report is essential for understanding the rapidly changing landscape of the IVD market and staying ahead in this dynamic industry.
Table: IVD Market excluding and with COVID-19, 2021 (in millions $)
| Segment | 2021 | %Mkt | YoY Growth |
| IVD Market excluding COVID-19 Assays and Instruments | $XX Million | XX% | XX% |
| COVID-19 Assays and Instruments | $XX Million | XX% | XX% |
| Total Market | $XX Million | XX% | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
Chapter One: Worldwide IVD Market – March 2022 Update
IVD Market Demand and Growth
- Figure 1-1: Quarter-by-Quarter Segment Performance Commentary, 2021
- Table 1-1: Global In Vitro Diagnostic Sales by Product Market, 2021 ($ million) (Clinical Chemistry; Immunoassays – non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c – lab; Hematology – Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology – Mass Spectrometry; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular – NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
- Figure 1-2: IVD Segment Performance, Q1 2021 – Q4 2021 ($MN)
- Figure 1-3: IVD Segment Performance, Total Market Value, 2021 ($MN)
COVID-19 Diagnostic Markets
Effect of COVID-19 on Market Segments
- Table 1-2: IVD Market excluding and with COVID-19, 2021
- Figure 1-4: IVD Market Distribution by Segment
- Table 1-3: Global In Vitro Diagnostic Market – YoY Growth 2020-2021
- Figure 1-5: Global In Vitro Diagnostic Market – YoY Growth 2020-2021
Chapter Two: Product Trends and New Developments
Selected New – Q4 2021 and Q1 2022 – Core IVD Product Launches, Developments and Trends
Clinical Chemistry
Flow Cytometry
Immunoassay
Mass Spectrometry
Molecular
Personalized Medicine
POC
Sequencing
COVID-19 Developments – Q1 2021 Through Q4 2021
- Figure 2-1: COVID-19 Test Market by Type, Q1-Q4 2021 Estimates – Rapid Testing Markets Remain Strong
Antigen
Molecular
Chapter Three: Top IVD Market Participant Results
Selected Competitive Leader Updates
- Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2020-2021
- Figure 3-2: Changes in Market Distribution for IVD Sales, 2019 & 2021 – Roche and Abbott Tie for #1 Spot
2021 M&A Activity
- Table 3-1: IVD-Relevant M&A Activity, 2021
- Figure 3-3: Count of IVD Industry M&A Deals by Month, 2021
Abbott Laboratories
- Table 3-2: Abbott Corporate Summary
- Figure 3-4: Abbott Diagnostics Revenue by Segment (Core Laboratory, Molecular, Point-of-Care, Rapid Diagnostics, COVID-19, BinaxNOW/ID NOW) Full Year 2020 and 2021
Becton Dickinson and Co
- Table 3-3: Becton Dickinson Corporate Summary
- Figure 3-5: BD Life Sciences, Revenues by Business FY End September 30, 2020, and 2021
bioMérieux SA
- Table 3-4: bioMérieux Corporate Summary
- Figure 3-6: bioMérieux Clinical Applications Segment, Full Year Results, 2020,2021
Danaher Corporation
- Table 3-5: Danaher Corporation Summary
- Figure 3-7: Danaher Diagnostic Segment Performance, Full Year Results, 2020,2021
Hologic, Inc.
- Table 3-6: Hologic Corporate Summary
- Figure 3-8: Hologic Diagnostic Segment Performance, Full Year Results, FY 2020, FY 2021, $M
Ortho Clinical Diagnostics
- Table 3-7: Ortho Clinical Corporate Summary
- Figure 3-9: Ortho Clinical Diagnostics, Full Year Results, $M (2020, 2021)
PerkinElmer, Inc.
- Table 3-8: Perkin Elmer Corporate Summary
- Figure 3-10: PerkinElmer Diagnostics (Product, Service Revenue), Full Year Results, $M (2020, 2021)
Quidel Corporation
- Table 3-9: Quidel Corporate Summary
- Figure 3-11: Quidel Corporation Revenue by Product Group, Full Year Results 2020, 2021, $M
Roche Diagnostic
- Table 3-10: Roche Diagnostic Corporate Summary
- Figure 3-12: Roche Diagnostics Revenue by Product Group, Full Year Results 2020, 2021, CHF MN
Siemens Healthineers
- Table 3-11: Siemens Healthineers Corporate Summary
- Figure 3-13: Siemens Diagnostics Revenue, FY 2020 and FY 2021, € MN
Sysmex Corporation
- Table 3-12: Sysmex Corporate Summary
- Figure 3-14: Sysmex Revenue by Product Segment, FY 2020, 2021 and 2022, JPY MN
Thermo Fisher Scientific
- Table 3-13: Thermo Fisher Scientific Corporate Summary
- Figure 3-15: Thermo Fisher Scientific COVID-19 Response Revenue, 2020 and 2021 by Quarter
Chapter Four: New Opportunities
Artificial Intelligence in the Lab
Multiplex and Syndromic Testing
Advancing Lateral Flow Technologies
Personalized Medicine
Point-of-Care
Mass Spectrometry-based COVID-19 Testing
Related products
COVID-19 Testing Markets, 2023
May 18, 2023
As the COVID-19 pandemic evolves into an endemic phase, the landscape of COVID-19 testing is changing rapidly. Kalorama Information’s COVID-19 Testing Markets, 2023 report provides crucial insights into this shifting market, answering key questions and providing valuable market sizing and estimates.
Key Insights Provided:
- Market impacts and trends in the evolving COVID-19 testing…
Price range: $4,000.00 through $6,000.00
The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 11th Edition
April 23, 2024
Explore the latest trends and forecasts in the point-of-care (POC) diagnostic tests market with Kalorama Information’s The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 11th Edition. Discover the key growth areas and technological advancements shaping the future of POC diagnostics.
Lab-based analyzers in hospitals and reference labs are the cornerstone of revenues in the in…
Price range: $7,000.00 through $10,000.00
The IVD Market in South Korea, 2024
February 26, 2024
Gain valuable insights into South Korea’s in vitro diagnostics (IVD) market with Kalorama Information’s comprehensive report, The IVD Market in South Korea, 2024. We offer a detailed analysis of South Korea’s IVD revenues for 2023 and forecasts for 2028, segmented into key categories such as clinical chemistry, immunoassay, microbiology/molecular testing, point-of-care (POC),…
Price range: $5,000.00 through $7,875.00
